Institutional members access full text with Ovid®

Share this article on:

Single-dose Pharmacokinetics and Tolerability of Daptomycin 8 to 10 mg/kg in Children Aged 2 to 6 Years With Suspected or Proved Gram-positive Infections

Abdel-Rahman, Susan M. PharmD*; Chandorkar, Gurudatt PhD†; Akins, Ronda L. PharmD‡§; Bradley, John S. MD¶∥; Jacobs, Richard F. MD**; Donovan, Julie BA†; Benziger, David P. PhD†

Pediatric Infectious Disease Journal: August 2011 - Volume 30 - Issue 8 - pp 712-714
doi: 10.1097/INF.0b013e31820fc8e1
Brief Reports

A pharmacokinetic analysis was performed for single intravenous doses of daptomycin 8 or 10 mg/kg in subjects aged 2 to 6 years. Proportional increases in maximum plasma concentration (68.4 μg/mL, 79.2 μg/mL) and area under the curve (429.1 μg · h/mL, 549.7 μg · h/mL) were observed for each dose cohort, respectively. Half-life, clearance, and distribution volume were similar between groups. Both doses were well tolerated.

From the *Division of Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospitals and Clinics, Kansas City, MO; †Cubist Pharmaceuticals, Inc., Lexington, MA; ‡Section of Infectious Diseases, Louisiana State University Health Sciences Center, Shreveport, LA; §Section of Infectious Diseases, University of Louisiana Monroe—Shreveport Campus, Shreveport, LA; ¶Section of Infectious Diseases, Rady Children's Hospital, San Diego, CA; ∥Section of Infectious Diseases, University of California, San Diego, CA; and **Section of Infectious Diseases, Arkansas Children's Hospital, Little Rock, AR.

Accepted for publication January 11, 2011.

Supported by Cubist Pharmaceuticals, Inc., for the conduct of this study and for professional medical writing and editorial assistance in the preparation of this manuscript. Cubist Pharmaceuticals and the University of Louisiana Monroe and consultancy fees from Targanta Therapeutics (to R.L.A.). Roche, AstraZeneca, Bristol-Myers Squibb, Johnson and Johnson, and Pfizer (to J.S.B).

Dr. Chandorkar is an employee and shareholder of Cubist Pharmaceuticals, Inc. and was an employee of Vertex Pharmaceuticals between 2000 and 2008. He currently owns stock in Vertex Pharmaceuticals and Allos Therapeutics and maintains personal relationships with employees at these companies. Dr. Benziger and Julie Donovan are employees and shareholders of Cubist Pharmaceuticals, Inc. Dr. Bradley has consulted for AstraZeneca, Bristol-Myers Squibb, Johnson and Johnson, and Bayer.

Drs. Abdel-Rahman and Jacobs have no conflicts of interest to report.

Address for correspondence: Susan M. Abdel-Rahman, PharmD, Children's Mercy Hospitals and Clinics, 2401 Gilham Road, Kansas City, MO 64108. E-mail: srahman@cmh.edu.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.pidj.com).

© 2011 by Lippincott Williams & Wilkins, Inc.